This iGEM team has been funded by the MSD Scottish Life Sciences Fund. As part of an ongoing contribution to Scottish life sciences, MSD Limited, a global healthcare leader has given substantial monetary funding to the Scottish Funding Council (SFC) for distribution via the Scottish Universities Life Sciences Alliance (SULSA) to develop and deliver a high quality drug discovery research and training programme. All aspects of the programme have been geared towards attaining the highest value in terms of scientific discovery, training and impact. The opinions expressed by this iGEM team are those of the team members and do not necessarily represent those of Merck Sharp&Dohme Limited nor its Affiliates.